COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Reslizumab in Chronic Rhinosinusitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02799446
Recruitment Status : Unknown
Verified January 2018 by Joshua S. Jacobs, Allergy and Asthma Clinical Research Inc..
Recruitment status was:  Recruiting
First Posted : June 14, 2016
Last Update Posted : February 1, 2018
Information provided by (Responsible Party):
Joshua S. Jacobs, Allergy and Asthma Clinical Research Inc.

Brief Summary:
The purpose of this study is to determine whether Reslizumab is effective for the treatment of chronic sinusitis.

Condition or disease Intervention/treatment Phase
Sinusitis Drug: Reslizumab Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Reslizumab for the Treatment of Chronic Rhinosinusitis A Double Blind, Randomized, Placebo-controlled, Phase III Trial
Study Start Date : June 2016
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sinusitis
Drug Information available for: Reslizumab

Arm Intervention/treatment
Experimental: Reslizumab
Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
Drug: Reslizumab
Reslizumab 3mg/kg intravenous (IV)

Placebo Comparator: Placebo
Matching placebo.
Drug: Placebo
Matching Placebo intravenous (IV)

Primary Outcome Measures :
  1. Change in computed tomography (CT) score [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Quality of life questionnaire [ Time Frame: 24 weeks ]
  2. Smell test [ Time Frame: 24 weeks ]
  3. Endoscopy score [ Time Frame: 24 weeks ]
  4. Adverse events by body system [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent
  2. Willingness and ability to comply with the requirements of the study
  3. Female or male patients ages 18-75 at the time of screening
  4. A diagnosis of chronic rhinosinusitis according to the clinical practice guideline (update) of the American academy of otolaryngology - head and neck surgery
  5. Elevated blood eosinophils
  6. Significant findings on computed tomography (CT) scan

Exclusion Criteria:

  1. Unable to sign informed consent form
  2. A woman that is pregnant or nursing a child
  3. Known hypersensitivity to Reslizumab
  4. Active cigarette smoking in the year prior to screening
  5. Known underlying immunodeficiency
  6. History of alcohol or drug abuse in the year prior to screening

Other criteria may apply. Please contact the investigator for more information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02799446

Layout table for location contacts
Contact: Study Coordinator 925-935-2599

Layout table for location information
United States, California
Allergy and Asthma Clinical Research Recruiting
Walnut Creek, California, United States, 94598
Contact    925-935-2599      
Sponsors and Collaborators
Joshua S. Jacobs
Layout table for investigator information
Principal Investigator: Joshua Jacobs, MD Allergy and Asthma Clinical Research

Layout table for additonal information
Responsible Party: Joshua S. Jacobs, MD, Allergy and Asthma Clinical Research Inc. Identifier: NCT02799446    
Other Study ID Numbers: AACR-01
First Posted: June 14, 2016    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018
Keywords provided by Joshua S. Jacobs, Allergy and Asthma Clinical Research Inc.:
sinusitis, rhinitis, rhinosinusitis, chronic
Additional relevant MeSH terms:
Layout table for MeSH terms
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Anti-Asthmatic Agents
Respiratory System Agents